Top Markets
#1 MowCat MowCat +48.44%
#2 Bermuda Shorts Bermuda Shorts +26.43%
#3 Velvet Velvet +25.14%
#4 Biconomy Biconomy +18.48%
#5 Quack AI Quack AI +18.37%
#6 Derive Derive +17.09%
#7 Block Street Block Street +15.53%
#8 DUSK Network DUSK Network +14.69%
#9 Perle Perle +14.22%
#10 Zerebro Zerebro +14.22%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Cellyan Biotechnology Co., Ltd Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd

HKPD
Rank in Stocks #34988
Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily... Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
Share Price
$0.422
Last synced: 2026-08-14
Market Cap
$4.63M
Change (1 day)
0.48%
Change (1 year)
-60.56%
Country
HK
Trade Cellyan Biotechnology Co., Ltd (HKPD)

Category

Healthcare
Revenue for Cellyan Biotechnology Co., Ltd (HKPD)
Revenue in Aug 2026 TTM: 0
According to Cellyan Biotechnology Co., Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cellyan Biotechnology Co., Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US